Hemophilia A Drugs Market Size

  • Report ID: 2422
  • Published Date: Jan 06, 2025
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Hemophilia is a condition in which the body is not able to form blood clots in order to stop bleeding. In a normal person’s body, the blood contains certain chemical substances which create a clot in case of bleeding. However, when a person has hemophilia, some clotting factors are absent which leads to the body being unable to form any clot. This result in continuous bleeding and eventually, severe loss of blood.

Hemophilia A is a rare genetic disorder of the blood characterized by a deficiency in the production of plasma protein factor VIII, which results in a reduced clotting property of the blood. Hemophilia drugs are given to hemophilic patients in order to provide them with these clotting factors artificially.

 



Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

North America industry is poised to account for largest revenue share by 2037, attributed to recent advancements in the healthcare industry as well as the research and development of new drugs.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos